Mirum Pharmaceuticals (MIRM) Revenue (2021 - 2026)

Mirum Pharmaceuticals' Revenue history runs 6 years deep, the most recent figure standing at $159.9 million for Q1 2026.

• In Q1 2026, Revenue rose 43.28% year-over-year to $159.9 million; the TTM figure through Mar 2026 stood at $569.6 million (up 50.19% YoY), while the FY2025 annual figure was $521.3 million, up 54.74% from the prior year.
• Revenue for Q1 2026 stood at $159.9 million, up from $148.9 million in the prior quarter.
• The five-year high for Revenue was $159.9 million in Q1 2026, with the low at $12.9 million in Q1 2022.
• The 5-year median for Revenue is $69.6 million (2023), against an average of $75.4 million.
• The sharpest annual moves came in 2022 and 2024: Revenue soared 789.29% in 2022, then jumped 42.93% in 2024.
• Mirum Pharmaceuticals' Revenue stood at $27.9 million in 2022, then surged by 149.24% to $69.6 million in 2023, then surged by 42.93% to $99.4 million in 2024, then jumped by 49.81% to $148.9 million in 2025, then advanced by 7.35% to $159.9 million in 2026.
• Business Quant data shows MIRM's Revenue at $159.9 million in Q1 2026, $148.9 million in Q4 2025, and $133.0 million in Q3 2025.